Algeta ASA of Norway has made Gillies O’Bryan-Tear chief medical officer (CMO) to help the company manage the final clinical development and registration of its radiopharmaceutical, Alpharadin (radium-223). Dr O’Bryan-Tear has been a consultant to the company since 2004, and acting CMO since March 2009. He has more than 20 years of experience in the pharmaceutical industry including senior positions managing and advising on the development and registration of new drugs and vaccines.
Alpharadin is being studied for the treatment of bone metastases in patients with hormone-refractory prostate cancer.
Copyright 2009 Evernow Publishing Ltd